In preparatory documents for the meeting, FDA staff said that it believed the evaluation criteria weigh against placing BPC-157 on the list because there was limited evidence about the peptides effectiveness and because there are other FDA-approved treatments for ulcerative colitis
Kady z tych tekstw mieci si w ramach research-only i nie stanowi porady medycznej ani prawnej
Koi Research Labs LLC is a chemical supplier, not a compounding pharmacy under 503A nor an outsourcing facility under 503B of the Federal Food, Drug, and Cosmetic Act
Calculate volume: Target concentration matters, e.g., for a 5 mg vial, 2 mL bacteriostatic water yields 2.5 mg/mL (easy dosing math)
BPC-157 demonstrates anti-inflammatory rather than direct antimicrobial effects
This reagent will keep your solutions free of contaminants and also inhibit the growth of germs, ensuring you can safely dissolve or store samples of peptides for long-term testing